Literature DB >> 31792057

The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable.

Susheel K Singh1, Jordan Plieskatt2, Bishwanath Kumar Chourasia1, Vandana Singh1, Judith M Bolscher3, Koen J Dechering3, Bright Adu4, Blanca López-Méndez5, Swarnendu Kaviraj6, Emily Locke2, C Richter King2, Michael Theisen7.   

Abstract

The Plasmodium falciparum circumsporozoite protein (PfCSP) is a sporozoite surface protein whose role in sporozoite motility and cell invasion has made it the leading candidate for a pre-erythrocytic malaria vaccine. However, production of high yields of soluble recombinant PfCSP, including its extensive NANP and NVDP repeats, has proven problematic. Here, we report on the development and characterization of a secreted, soluble, and stable full-length PfCSP (containing 4 NVDP and 38 NANP repeats) produced in the Lactococcus lactis expression system. The recombinant full-length PfCSP, denoted PfCSP4/38, was produced initially with a histidine tag and purified by a simple two-step procedure. Importantly, the recombinant PfCSP4/38 retained a conformational epitope for antibodies as confirmed by both in vivo and in vitro characterizations. We characterized this complex protein by HPLC, light scattering, MS analysis, differential scanning fluorimetry, CD, SDS-PAGE, and immunoblotting with conformation-dependent and -independent mAbs, which confirmed it to be both pure and soluble. Moreover, we found that the recombinant protein is stable at both frozen and elevated-temperature storage conditions. When we used L. lactis-derived PfCSP4/38 to immunize mice, it elicited high levels of functional antibodies that had the capacity to modify sporozoite motility in vitro We concluded that the reported yield, purity, results of biophysical analyses, and stability of PfCSP4/38 warrant further consideration of using the L. lactis system for the production of circumsporozoite proteins for preclinical and clinical applications in malaria vaccine development.
© 2020 Singh et al.

Entities:  

Keywords:  Lactococcus lactis; Plasmodium falciparum; chromatography; circumsporozoite protein; immunogenicity; malaria; parasite; protein expression; protein folding; vaccine development

Mesh:

Substances:

Year:  2019        PMID: 31792057      PMCID: PMC6956534          DOI: 10.1074/jbc.RA119.011268

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; Solange Solmeheim Soulanoudjingar; José Francisco Fernandes; Béatrice Peggy Abossolo; Cornelia Conzelmann; Barbara Gaelle Nfono Ondo Methogo; Yannick Doucka; Arnaud Flamen; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Arlindo Nhamuave; Diana Quelhas; Quique Bassat; Sofia Mandjate; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Omar Juma; Mwanajaa Shomari; Kafuruki Shubis; Francisca Machera; Ali Said Hamad; Rose Minja; Ali Mtoro; Alma Sykes; Saumu Ahmed; Alwisa Martin Urassa; Ali Mohammed Ali; Grace Mwangoka; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Marc Christian Tahita; William Kaboré; Sayouba Ouédraogo; Yara Sandrine; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Chris Odero; Martina Oneko; Kephas Otieno; Norbert Awino; Jackton Omoto; John Williamson; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Otsyula Nekoye; Stacey Gondi; Allan Otieno; Bernhards Ogutu; Ruth Wasuna; Victorine Owira; David Jones; Agnes Akoth Onyango; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Jesse Gitaka; Charity Maingi; Trudie Lang; Ally Olotu; Benjamin Tsofa; Philip Bejon; Norbert Peshu; Kevin Marsh; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; Samuel Ayamba; Kingsley Kayan; Ruth Owusu-Ofori; David Dosoo; Isaac Asante; George Adjei; George Adjei; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Hassan Kilavo; Coline Mahende; Edwin Liheluka; Martha Lemnge; Thor Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Alex Agyekum; Larko Owusu; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Ruthendo Nkomo; Albans Msika; Allan Jumbe; Nelecy Chome; Dalitso Nyakuipa; Joseph Chintedza; W Ripley Ballou; Myriam Bruls; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Johan Vekemans; Terrell Carter; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

2.  Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine.

Authors:  J F Young; W T Hockmeyer; M Gross; W R Ballou; R A Wirtz; J H Trosper; R L Beaudoin; M R Hollingdale; L H Miller; C L Diggs
Journal:  Science       Date:  1985-05-24       Impact factor: 47.728

3.  Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains.

Authors:  Raul Herrera; Charles Anderson; Krishan Kumar; Alvaro Molina-Cruz; Vu Nguyen; Martin Burkhardt; Karine Reiter; Richard Shimp; Randall F Howard; Prakash Srinivasan; Michael J Nold; Daniel Ragheb; Lirong Shi; Mark DeCotiis; Joan Aebig; Lynn Lambert; Kelly M Rausch; Olga Muratova; Albert Jin; Steven G Reed; Photini Sinnis; Carolina Barillas-Mury; Patrick E Duffy; Nicholas J MacDonald; David L Narum
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

4.  Plasmodium falciparum: glycosylation status of Plasmodium falciparum circumsporozoite protein expressed in the baculovirus system.

Authors:  Mamdouh H Kedees; Nahid Azzouz; Peter Gerold; Hosam Shams-Eldin; Jahangir Iqbal; Volker Eckert; Ralph T Schwarz
Journal:  Exp Parasitol       Date:  2002-05       Impact factor: 2.011

Review 5.  A research agenda to underpin malaria eradication.

Authors:  Pedro L Alonso; Graham Brown; Myriam Arevalo-Herrera; Fred Binka; Chetan Chitnis; Frank Collins; Ogobara K Doumbo; Brian Greenwood; B Fenton Hall; Myron M Levine; Kamini Mendis; Robert D Newman; Christopher V Plowe; Mario Henry Rodríguez; Robert Sinden; Laurence Slutsker; Marcel Tanner
Journal:  PLoS Med       Date:  2011-01-25       Impact factor: 11.069

6.  IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.

Authors:  Robert Schwenk; Margot DeBot; Michael Porter; Jennifer Nikki; Lisa Rein; Roberta Spaccapelo; Andrea Crisanti; Paul D Wightman; Christian F Ockenhouse; Sheetij Dutta
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

7.  Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.

Authors:  Katharine A Collins; Rebecca Snaith; Matthew G Cottingham; Sarah C Gilbert; Adrian V S Hill
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

8.  Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children.

Authors:  Liriye Kurtovic; Marije C Behet; Gaoqian Feng; Linda Reiling; Kiprotich Chelimo; Arlene E Dent; Ivo Mueller; James W Kazura; Robert W Sauerwein; Freya J I Fowkes; James G Beeson
Journal:  BMC Med       Date:  2018-04-30       Impact factor: 8.775

9.  Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes.

Authors:  U Frevert; P Sinnis; C Cerami; W Shreffler; B Takacs; V Nussenzweig
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

10.  Cell-passage activity is required for the malarial parasite to cross the liver sinusoidal cell layer.

Authors:  Tomoko Ishino; Kazuhiko Yano; Yasuo Chinzei; Masao Yuda
Journal:  PLoS Biol       Date:  2004-01-20       Impact factor: 8.029

View more
  8 in total

1.  Method for Production of Cysteine-Rich Proteins in Lactococcus lactis Expression System.

Authors:  Susheel K Singh; Vandana Singh
Journal:  Methods Mol Biol       Date:  2022

2.  Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates.

Authors:  Roos M de Jong; Susheel K Singh; Karina Teelen; Marga van de Vegte-Bolmer; Geert-Jan van Gemert; Will J R Stone; Emily Locke; Jordan Plieskatt; Michael Theisen; Teun Bousema; Matthijs M Jore
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

3.  Probiotics Surface-Delivering Fiber2 Protein of Fowl Adenovirus 4 Stimulate Protective Immunity Against Hepatitis-Hydropericardium Syndrome in Chickens.

Authors:  Zhipeng Jia; Xinghui Pan; Wenjing Zhi; Hang Chen; Bingrong Bai; Chunli Ma; Dexing Ma
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

4.  A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria.

Authors:  Manisha Pritam; Garima Singh; Suchit Swaroop; Akhilesh Kumar Singh; Brijesh Pandey; Satarudra Prakash Singh
Journal:  Int J Biol Macromol       Date:  2020-04-29       Impact factor: 6.953

5.  A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine.

Authors:  Susheel K Singh; Jordan Plieskatt; Bishwanath K Chourasia; Amanda Fabra-García; Asier Garcia-Senosiain; Vandana Singh; Karin Lövgren Bengtsson; Jenny M Reimer; Robert Sauerwein; Matthijs M Jore; Michael Theisen
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

6.  Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages.

Authors:  Wei-Chiao Huang; Moustafa T Mabrouk; Luwen Zhou; Minami Baba; Mayumi Tachibana; Motomi Torii; Eizo Takashima; Emily Locke; Jordan Plieskatt; C Richter King; Camila H Coelho; Patrick E Duffy; Carole Long; Takafumi Tsuboi; Kazutoyo Miura; Yimin Wu; Tomoko Ishino; Jonathan F Lovell
Journal:  Commun Biol       Date:  2022-08-01

7.  Oral Immunization With a M Cell-Targeting Recombinant L. Lactis Vaccine LL-plSAM-FVpE Stimulate Protective Immunity Against H. Pylori in Mice.

Authors:  Le Guo; Furui Zhang; Shue Wang; Runle Li; Lele Zhang; Zhen Zhang; Runting Yin; Hongpeng Liu; Kunmei Liu
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

Review 8.  Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.

Authors:  Romina Levit; Naima G Cortes-Perez; Alejandra de Moreno de Leblanc; Jade Loiseau; Anne Aucouturier; Philippe Langella; Jean Guy LeBlanc; Luis G Bermúdez-Humarán
Journal:  Gut Microbes       Date:  2022 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.